Fractyl health, inc. common stock GUTS.US Overview
GUTS AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
GUTS Current Performance
-1.09%
Fractyl health, inc. common stock
-0.34%
Avg of Sector
-1.60%
S&P500
GUTS Key Information
GUTS Revenue by Segments
Browsing restrictions can be lifted for a fee.
GUTS Net Income
Browsing restrictions can be lifted for a fee.
GUTS Cash Flow
Browsing restrictions can be lifted for a fee.
GUTS Profit Margin
Browsing restrictions can be lifted for a fee.
GUTS PE Ratio River
Browsing restrictions can be lifted for a fee.
GUTS Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
GUTS Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
GUTS Profile
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
Price of GUTS
GUTS FAQ
When is GUTS's latest earnings report released?
The most recent financial report for Fractyl health, inc. common stock (GUTS) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GUTS's short-term business performance and financial health. For the latest updates on GUTS's earnings releases, visit this page regularly.
How is GUTS's revenue growth?
In the latest financial report, Fractyl health, inc. common stock (GUTS) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does GUTS have?
As of the end of the reporting period, Fractyl health, inc. common stock (GUTS) had total debt of 61.43M, with a debt ratio of 0.74. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does GUTS have?
At the end of the period, Fractyl health, inc. common stock (GUTS) held Total Cash and Cash Equivalents of 42.11M, accounting for 0.51 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is GUTS's EPS continuing to grow?
According to the past four quarterly reports, Fractyl health, inc. common stock (GUTS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.49. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of GUTS?
Fractyl health, inc. common stock (GUTS)'s Free Cash Flow (FCF) for the period is -25.53M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 99.9% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.